Quick Answer
Instil Bio, Inc. reported Cash And Cash Equivalents At Carrying Value of $6.64 million for the year ending 2025.
- Instil Bio, Inc. showed a decrease of -24.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Instil Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $609.64 million | Q2 2021: $566.73 million | Q3 2021: $20.40 million | Q1 2022: $61.47 million | Q2 2022: $42.46 million | Q3 2022: $41.12 million | Q1 2023: $27.35 million | Q2 2023: $21.76 million | Q3 2023: $9.13 million | Q1 2024: $5.48 million | Q2 2024: $6.78 million | Q3 2024: $6.66 million | Q1 2025: $15.37 million | Q2 2025: $7.69 million | Q3 2025: $5.80 million.
- Over the full 6 years of available data (2020 to 2025), Instil Bio, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 97.3%.
- Historical annual values: Fiscal year 2025: $6.64 million | Fiscal year 2024: $8.81 million | Fiscal year 2023: $9.20 million | Fiscal year 2022: $43.72 million | Fiscal year 2021: $37.59 million | Fiscal year 2020: $241.71 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: